IMR Press / EJGO / Volume 22 / Issue 3 / pii/2001149

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Case Report

Reduction of visible bone metastases by clodronate therapy in breast cancer

Show Less
1 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospital Antwerp, Antwerp, Belgium
2 Division of Haematology, University Hospital Antwerp, Antwerp, Belgium
Eur. J. Gynaecol. Oncol. 2001, 22(3), 215–216;
Published: 10 June 2001

The current report describes a 57-year-old patient with multiple bone metastases 14 years after her initial treatment for breast cancer. The only therapy the patient received for her osteolytic lesions was oral clodronate (800 mg/daily), as she refused any other kind of treatment. On bone scintigraphy the number of visible bone metastases diminished slowly and after two years only a few minor lesions could be seen. Together with this report the value of oral clodronate as anti-osteolytic therapy in breast cancer patients is discussed.

Bone metastases
Breast cancer
Clodronate therapy
Back to top